ADGM

Adagio Medical Holdings, Inc. operates as a medical device company focused on developing and commercializing innovative technologies for cardiac arrhythmia treatment. Headquartered in Laguna Hills, California, the company specializes in cryoablation systems designed to treat atrial fibrillation and other cardiac rhythm disorders. Adagio's flagship product, the iCLAS Cryoablation System, utilizes intelligent Continuous Lesion Ablation System technology to create contiguous lesions during cardiac ablation procedures. The system features real-time monitoring capabilities and aims to improve procedural efficiency while reducing complications associated with traditional ablation methods. The company targets the electrophysiology market, competing in a sector dominated by radiofrequency ablation technologies. Adagio remains in the commercial development stage, working to secure regulatory approvals and expand its market presence. The company received CE Mark approval in Europe, allowing commercialization in European markets, while pursuing FDA approval for the United States market. As a clinical-stage medical device company, Adagio continues to conduct clinical trials and gather evidence supporting its technology's safety and efficacy. The company collaborates with leading electrophysiologists and cardiac centers to refine its platform and establish clinical validation for its cryoablation approach in treating cardiac arrhythmias.